Key result
Ghanaian HF cohort shows 100% frusemide use but low ACEi and beta-blocker prescription rates.
Observational (n=100)
No
An audit of heart failure management at a Ghanaian teaching hospital revealed high use of frusemide and ACE inhibitors, but suboptimal utilization of beta-blockers compared to ESC guidelines.
Suboptimal beta-blocker use in this Ghanaian cohort signals need for local quality review; leaves open whether similar gaps exist across sub-Saharan Africa.
This study was done to compare the treatment of heart failure at the Komfo Anokye Teaching Hospital (KATH), Kumasi, with the European Society of Cardiology (ESC) guidelines for the treatment of heart failure. Patients above twelve years admitted to the medical wards with heart failure were recruited. Detailed history was obtained. Clinical examination, and laboratory investigations were done. Treatments received by the patients whilst on admission were studied and compared with the ESC guidelines for the treatment of heart failure. Hundred patients were studied; 52 males and 48 females, aged 14-100 years with mean 56.15 ( 18.50) years. Every patient received frusemide. ACE-I were used in 83.3%, 51.7 % and 55.4 % of the patients with NYHA classes II, III, and IV respectively. Beta-blockers were used in 33.3%, 20.7% and 12.3% of patients with NYHA classes II, III and IV respectively. In conclusion, frusemide and ACE-I were the two most common drugs prescribed.
No takes yet. Share an insight, caveat, or question.
A 2007 study conducted an observational in Heart failure (n=100). Heart failure treatment practices vs. European Society of Cardiology (ESC) guidelines was evaluated on Medication use by NYHA class. Among 100 heart failure patients in a Ghanaian hospital, 100% received frusemide, while ACE inhibitors and beta-blockers were used in 51.7-83.3% and 12.3-33.3% of patients across NYHA classes II-IV.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: